|
1.
|
|
18 p, 2.0 MB |
Persistence of Chronic Lymphocytic Leukemia Stem-like Populations under Simultaneous In Vitro Treatment with Curcumin, Fludarabine, and Ibrutinib : Implications for Therapy Resistance
/
Bistué-Rovira, Àngel (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
G. Rico, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bardina, Jorge (Vall d'Hebron Institut d'Oncologia) ;
Junca, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bradford, Jolene A. (Thermo Fisher Scientific (Estats Units d'Amèrica)) ;
Ward, Michael D. (Thermo Fisher Scientific (Estats Units d'Amèrica)) ;
Salvia, Roser (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Petriz, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Leukemic stem cells (LSCs) possess similar characteristics to normal hematopoietic stem cells, including self-renewal capacity, quiescence, ability to initiate leukemia, and drug resistance. These cells play a significant role in leukemia relapse, persisting even after apparent remission. [...]
2024 -  10.3390/ijms25041994
International journal of molecular sciences, Vol. 25, Num. 4 (february 2024)
|
|
|
2.
|
|
17 p, 921.2 KB |
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
/
Sauta, Elisabetta (Humanitas Clinical and Research Center (Itàlia)) ;
Robin, Marie (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Bersanelli, Mateo (Department of Biomedical Sciences. Humanitas University) ;
Travaglino, Erica (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Meggendorfer, Manje (Mll Munich Leukemia Laboratory) ;
Zhao, Lin-Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Caballero Berrocal, Juan Carlos (Hematology Department. Hospital Universitario de Salamanca) ;
Sala, Claudia (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Maggioni, Giulia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bernardi, Massimo (University Vita-Salute San Raffaele (Itàlia)) ;
Di Grazia, Carmen (Irccs Ospedale Policlinico San Martino) ;
Vago, Luca (University Vita-Salute San Raffaele (Itàlia)) ;
Rivoli, Giulia (Irccs Ospedale Policlinico San Martino) ;
Borin, Lorenza (Ospedale San Gerardo) ;
D'Amico, Saverio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Tentori, Cristina Astrid (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Ubezio, Marta (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Campagna, Alessia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Russo, Antonio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Mannina, Daniele (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Lanino, Luca (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Chiusolo, Patrizia (Università Cattolica Del Sacro Cuore) ;
Giaccone, Luisa (Department of Molecular Biotechnology and Health Sciences. University of Turin) ;
Voso, Maria Teresa (Tor Vergata University) ;
Riva, Maria (Asst Grande Ospedale Metropolitano Niguarda) ;
Oliva, Esther Natalie (Grande Ospedale Metropolitano Bianchi Melacrino Morelli) ;
Zampini, Matteo (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Riva, Elena (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Nibourel, Olivier (Chu Lille) ;
Bicchieri, Marinela (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bolli, Niccolo (Department of Oncology and Hemato-Oncology. University of Milan) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni Xxiii) ;
Passamonti, Francesco (Department of Medicine and Surgery. University of Insubria) ;
Savevski, Victor (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Santoro, Armando (Department of Biomedical Sciences. Humanitas University) ;
Germing, Ulrich (Department of Hematology. Heinrich-Heine-University. University Clinic) ;
Kordasti, Shahram (Hematology Department. DISCLIMO-Università Politecnica Delle Marche) ;
Santini, Valeria (University of Florence) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Sole, F (Institut de Recerca Contra la Leucèmia Josep Carreras) ;
Kern, Wolfgang (Mll Munich Leukemia Laboratory) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Arenillas, Leonor (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Fenaux, Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Haferlach, Torsten (Mll Munich Leukemia Laboratory) ;
Castellani, Gastone (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Della Porta, Matteo Giovanni (Department of Biomedical Sciences. Humanitas University)
PURPOSEMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). [...]
2023 - 10.1200/JCO.22.01784
Journal of Clinical Oncology, Vol. 41 Núm. 15 (20 2023) , p. 2827-2842
|
|
|
3.
|
|
13 p, 1.6 MB |
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8
/
Toribio-Castelló, Sofía (CIBERONC. Research Group CB16/12/00233) ;
Castaño-Díez, Sandra (Hospital Clínic i Provincial de Barcelona) ;
Villaverde-Ramiro, Ángela (Universidad de Salamanca) ;
Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ;
Arnan, Montserrat (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Díaz-Beyá, Marina (Hospital Clínic i Provincial de Barcelona) ;
Díez-Campelo, María (CIBERONC. Research Group CB16/12/00233) ;
del Rey, Mónivs (Hospital Universitario de Salamanca) ;
González, Teresa (Hospital Universitario de Salamanca) ;
Hernández-Rivas, Jesús María (CIBERONC. Research Group CB16/12/00233)
Trisomy 8 (+8) is the most frequent trisomy in myelodysplastic syndromes (MDS) and is associated with clinical heterogeneity and intermediate cytogenetic risk when found in isolation. The presence of gene mutations in this group of patients and the prognostic significance has not been extensively analyzed. [...]
2023 - 10.3390/cancers15153822
Cancers, Vol. 15 Núm. 15 (august 2023) , p. 3822
|
|
|
4.
|
|
12 p, 801.4 KB |
The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
/
Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mestre, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jerez, Andrés (Vall d'Hebron Institut d'Oncologia) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. [...]
2023 - 10.3390/cancers15051483
Cancers, Vol. 15 Núm. 5 (march 2023) , p. 1483
|
|
|
5.
|
|
10 p, 1.3 MB |
Two-Time Multiplexed Targeted Next-Generation Sequencing Might Help the Implementation of Germline Screening Tools for Myelodysplastic Syndromes/Hematologic Neoplasms
/
Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mestre, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Risueño, Ruth M. (University of Atlántico Medio, Las Palmas) ;
Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Next-generation sequencing (NGS) tools have importantly helped the classification of myelodysplastic syndromes (MDS), guiding the management of patients. However, new concerns are under debate regarding their implementation in routine clinical practice for the identification of germline predisposition. [...]
2023 - 10.3390/biomedicines11123222
Biomedicines, Vol. 11 Núm. 12 (december 2023)
|
|
|
6.
|
|
30 p, 7.3 MB |
Single-Cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy
/
Campillo-Marcos, Ignacio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Casado Pelaez, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mata, Caterina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mereu, Elisabetta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Valcárcel, David (Vall d'Hebron Institut d'Oncologia) ;
Molero, Antonieta (Hospital Universitari Vall d'Hebron) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Acha, Pamela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Manzanares Mileo, Ana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tobiasson, Magnus (Karolinska Institutet (Estocolm, Suècia)) ;
Hellström-Lindberg, Eva (Karolinska Institutet (Estocolm, Suècia)) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMAs), such as azacitidine (AZA), have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia (AML). [...]
2024 - 10.1158/2767-9764.CRC-23-0389
Cancer Research Communications, Vol. 4 Núm. 2 (2024)
|
|
|
7.
|
|
4 p, 551.6 KB |
Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
/
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tuechler, Heinz (Boltzmann Institute for Leukaemia Research and Hematology) ;
Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ;
Raynaud, Sophie (Cote d'Azur University) ;
Cluzeau, Thomas (Cote d'Azur University) ;
Shih, Lee-Yung (Chang Gung University) ;
Tung-Liang, Chiang (Chang Gung University) ;
Ganster, Christina (University Medical Center Göttingen) ;
Shirneshan, Katayoon (University Medical Center Göttingen) ;
Haase, Detlef (University Medical Center Göttingen) ;
Mascaró, Martí (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Palomo Sanchís, Laura (Vall d'Hebron Institut d'Oncologia) ;
Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ;
Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ;
Trim, Nicola (Birmingham Women's Hospital) ;
Jeffries, Sally (Birmingham Women's Hospital) ;
Ridgway, Emma (Birmingham Women's Hospital) ;
Marconi, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ;
Martinelli, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of genomic microarrays. [...]
2023 - 10.1002/jha2.651
EJHaem, Vol. 4 (february 2023) , p. 446-449
|
|
|
8.
|
|
14 p, 1.0 MB |
CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
/
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Barrera, Susana (Universidad de Salamanca) ;
Bataller, Alex (Hospital Clínic i Provincial de Barcelona) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Elliot, Natalina (John Radcliffe Hospital (Oxford, Regne Unit)) ;
O'Byrne, Sorcha (John Radcliffe Hospital (Oxford, Regne Unit)) ;
Wang, Guanlin (University of Oxford) ;
Rovira, Montse (University of Oxford) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Trincado Alonso, Juan Luis, 1987- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-González, María (Universidad de Salamanca) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sorigue, Marc (Universitat Autònoma de Barcelona) ;
Bárcena, Paloma (Universidad de Salamanca) ;
Zanetti, S. R (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Torrebadell, Montse (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Vega-Garcia, Nerea (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Rives, Susana (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Mallo, Maria del Mar (Universitat Autònoma de Barcelona) ;
Sole, F (Universitat Autònoma de Barcelona) ;
Mead, Adam J. (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Roberts, Irene (Oxford Biomedical Research Centre) ;
Thongjuea, Supat (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Psaila, Bethan (Oxford Biomedical Research Centre) ;
Juan, Manel (Hospital Clínic i Provincial de Barcelona) ;
Delgado, Julio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizúa, Alvaro (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ribera, Jose-Maria (Universitat Autònoma de Barcelona) ;
Orfao, Alberto (Universidad de Salamanca) ;
Roy, Anindita (Oxford Biomedical Research Centre) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered by difficulty in identifying a target antigen that is not also expressed on healthy T cells, risking "fratricide" with T-cell aplasia and loss of the CAR-T cells. [...]
2022 - 10.1182/blood.2021014840
Blood, Vol. 140 (july 2022) , p. 38-44
|
|
|
9.
|
|
14 p, 9.2 MB |
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 -Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
/
Ademà, Vera (The University of Texas MD Anderson Cancer Center) ;
Ma, Feiyang (University of Michigan) ;
Kanagal-Shamanna, Rashmi (The University of Texas MD Anderson Cancer Center) ;
Thongon, Natthakan (The University of Texas MD Anderson Cancer Center) ;
Montalban-Bravo, Guillermo (The University of Texas) ;
Yang, Hui (The University of Texas) ;
Peslak, Scott A. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Wang, Feng (The University of Texas MD Anderson Cancer Center) ;
Acha, Pamela (Universitat Autònoma de Barcelona) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lockyer, Pamela (The University of Texas MD Anderson Cancer Center) ;
Cassari, Margherita (University of Florence) ;
Maciejewski, Jaroslaw P. (Cleveland Clinic Foundation) ;
Visconte, Valeria (Cleveland Clinic Foundation) ;
Gañán-Gómez, Irene (The University of Texas MD Anderson Cancer Center) ;
Song, Yuanbin (Sun Yat-sen University Cancer Center) ;
Bueso-Ramos, Carlos (The University of Texas MD Anderson Cancer Center) ;
Pellegrini, Matteo (University of California) ;
Tan, Tuyet M. (Univerity of California San Diego) ;
Bejar, Rafael (Univerity of California San Diego) ;
Carew, Jennifer S. (University of Arizona Cancer Center) ;
Halene, Stephanie (Yale University School of Medicine) ;
Santini, Valeria (University of Florence) ;
Al-Atrash, Gheath (The University of Texas MD Anderson Cancer Center) ;
Clise-Dwyer, Karen (The University of Texas MD Anderson Cancer Center) ;
Garcia-Manero, Guillermo (The University of Texas MD Anderson Cancer Center) ;
Blobel, Gerd A. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Colla, Simona (The University of Texas MD Anderson Cancer Center)
SF3B1 -mutant MDS-RS is associated with buildup of erythroid progenitor cells upregulating EIF2AK1-associated heme deficiency response and autophagy genes. Targeting EIF2AK1 relieves the dysregulated progenitor phenotype. [...]
2022 - 10.1158/2643-3230.BCD-21-0220
Blood Cancer Discovery, Vol. 3 (august 2022) , p. 554-567
|
|
|
10.
|
|
13 p, 3.0 MB |
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
/
Ademà, Vera (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Walter, Wencke (Munich Leukemia Laboratory) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hutter, Stephan (Munich Leukemia Laboratory) ;
La Framboise, Thomas (Department of Genetics and Genome Sciences. Case Western Reserve University) ;
Arenillas, Leonor (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Meggendorfer, Manja (Munich Leukemia Laboratory) ;
Radivoyevitch, Tomas (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pellagatti, Andrea (Blood Cancer UK Molecular Haematology Unit. Nuffield Division of Clinical Laboratory Sciences. Radcliffe Department of Medicine. University of Oxford and Oxford BRC Haematology Theme) ;
Haferlach, Claudia (Munich Leukemia Laboratory) ;
Boultwood, Jacqueline (University of Oxford. Radcliffe Department of Medicine) ;
Kern, Wolfgang (Munich Leukemia Laboratory) ;
Visconte, Valeria (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ;
Sekeres, Mikkael (Leukemia Program. Department of Hematology and Medical Oncology. Cleveland Clinic. Cleveland Clinic Taussig Cancer Institute) ;
Barnard, John (Department of Quantitative Health Sciences. Cleveland Clinic. Lerner Research Institute) ;
Haferlach, Torsten (Munich Leukemia Laboratory) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Maciejewski, Jaroslaw (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute)
Background: Haploinsufficiency (HI) resulting from deletion of the long arm of chromosome 5 [del(5q)] and the accompanied loss of heterozygosity are likely key pathogenic factors in del(5q) myeloid neoplasia (MN) although the consequences of del(5q) have not been yet clarified. [...]
2022 - 10.1016/j.ebiom.2022.104059
EBioMedicine, Vol. 80 (june 2022) , art. 104059
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
